Tudor Investment Corp ET AL Sells 320,361 Shares of NeoGenomics, Inc.

The hedge fund lowered its stake in the medical research company by 46% in the third quarter.

Mar. 28, 2026 at 11:14am

Got story updates? Submit your updates here. ›

An extreme close-up of various gears, levers, and dials of industrial financial machinery, conveying the complex, institutional nature of investment management decisions.A hedge fund's reduction in its stake in a leading cancer diagnostics company reflects broader shifts in the healthcare investment landscape.Fort Myers Today

According to a recent SEC filing, Tudor Investment Corp ET AL reduced its position in NeoGenomics, Inc. (NASDAQ:NEO) by selling 320,361 shares in the third quarter. The hedge fund now owns 375,351 shares, or about 0.29% of the medical research company's stock, down from its previous stake of 695,712 shares.

Why it matters

This transaction highlights the changing investment landscape around NeoGenomics, a leading provider of cancer-focused genetic and molecular testing services. The sale by Tudor Investment Corp ET AL, a prominent hedge fund, could signal broader shifts in investor sentiment or portfolio adjustments within the healthcare and biotech sectors.

The details

In its 13F filing with the SEC, Tudor Investment Corp ET AL reported selling 320,361 shares of NeoGenomics, reducing its stake by 46% during the third quarter. The hedge fund now holds 375,351 shares, worth approximately $2.9 million based on the stock's closing price on the last day of the reporting period.

  • The transaction occurred in the third quarter of 2026.

The players

Tudor Investment Corp ET AL

A prominent hedge fund that has reduced its position in NeoGenomics, Inc.

NeoGenomics, Inc.

A leading provider of cancer-focused genetic and molecular testing services, traded on the Nasdaq under the symbol NEO.

Got photos? Submit your photos here. ›

What they’re saying

“We must continue to monitor changes in institutional ownership and investor sentiment around NeoGenomics as the company navigates the evolving healthcare and biotech landscape.”

— Analyst

What’s next

Investors and analysts will likely be closely watching for any further changes in institutional holdings of NeoGenomics stock, as well as the company's upcoming financial results and strategic initiatives.

The takeaway

The sale by Tudor Investment Corp ET AL represents a notable shift in the investment landscape around NeoGenomics, a prominent player in the cancer diagnostics and genomics testing market. This transaction underscores the need for ongoing monitoring of ownership changes and broader industry trends that may impact the company's performance and outlook.